intralesional propranolol injection — Competitive Intelligence Brief

intralesional propranolol injection (intralesional propranolol injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist. Area: Dermatology / Oncology.

marketed Beta-adrenergic antagonist Beta-adrenergic receptors (non-selective) Dermatology / Oncology Small molecule

Target snapshot

intralesional propranolol injection (intralesional propranolol injection) — Ain Shams University. Intralesional propranolol injection blocks beta-adrenergic receptors within hemangioma tissue, reducing angiogenesis and promoting vascular regression.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intralesional propranolol injection TARGET	intralesional propranolol injection	Ain Shams University	marketed	Beta-adrenergic antagonist	Beta-adrenergic receptors (non-selective)
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
oral Propranolol	oral Propranolol	Ahmed talaat ahmed aly	marketed	Non-selective beta-adrenergic antagonist (beta-blocker)	Beta-1 and beta-2 adrenergic receptors
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Combigan Ophthalmic Solutiom	Combigan Ophthalmic Solutiom	Genovate Biotechnology Co., Ltd.,	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist	Alpha-2 adrenergic receptors and beta-adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
timolol maleate and dorzolamide hydrochloride	timolol maleate and dorzolamide hydrochloride	University of Florida	marketed	Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination	Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist class)

1. Ain Shams University · 1 drug in this class
2. Policlinico Casilino ASL RMB · 1 drug in this class
3. Unity Health Toronto · 1 drug in this class
4. University of California, Davis · 1 drug in this class